Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Role of Platinum Compounds for the Treatment of Breast Cancer

The Role of Platinum Compounds for the Treatment of Breast Cancer Platinum compounds have recently resurged as promising old agents for treatment of breast cancer in some specific subgroups of patients. The recognition of breast cancer as a heterogeneous disease with a genomic classification of at least 4 subtypes, the fact that platinum compounds could synergistically enhance anti-HER2 efficacy in the HER2 positive breast cancer, and the observation that platinum derivates were highly active in tumors with homologous recombination deficiency, such as BRCA-associated or basal-like breast cancer, have raised the interest in cisplatin and carboplatin. This review will focus on the recent data published regarding the use of these agents in monotherapy or in combination, and will shed some light on the challenges currently facing the use of these compounds in the standard care of our breast cancer patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

The Role of Platinum Compounds for the Treatment of Breast Cancer

Loading next page...
 
/lp/springer-journals/the-role-of-platinum-compounds-for-the-treatment-of-breast-cancer-t5DjJwiFSk

References (67)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-012-0100-x
Publisher site
See Article on Publisher Site

Abstract

Platinum compounds have recently resurged as promising old agents for treatment of breast cancer in some specific subgroups of patients. The recognition of breast cancer as a heterogeneous disease with a genomic classification of at least 4 subtypes, the fact that platinum compounds could synergistically enhance anti-HER2 efficacy in the HER2 positive breast cancer, and the observation that platinum derivates were highly active in tumors with homologous recombination deficiency, such as BRCA-associated or basal-like breast cancer, have raised the interest in cisplatin and carboplatin. This review will focus on the recent data published regarding the use of these agents in monotherapy or in combination, and will shed some light on the challenges currently facing the use of these compounds in the standard care of our breast cancer patients.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Jan 6, 2013

There are no references for this article.